Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

NCT00494234 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Olaparib

Sponsor

AstraZeneca

Collaborators

[object Object]